Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2024

Open Access 01-12-2024 | Status Epilepticus | Study Protocol

Sustained effort network for treatment of status epilepticus/European academy of neurology registry on adult refractory status epilepticus (SENSE-II/AROUSE)

Authors: Charlotte Damien, Markus Leitinger, Christoph Kellinghaus, Adam Strzelczyk, Pia De Stefano, Christoph P. Beier, Raoul Sutter, Leena Kämppi, Daniel Strbian, Erik Taubøll, Felix Rosenow, Raimund Helbok, Stephan Rüegg, Maxwell Damian, Eugen Trinka, Nicolas Gaspard

Published in: BMC Neurology | Issue 1/2024

Login to get access

Abstract

Background

Status Epilepticus (SE) is a common neurological emergency associated with a high rate of functional decline and mortality. Large randomized trials have addressed the early phases of treatment for convulsive SE. However, evidence regarding third-line anesthetic treatment and the treatment of nonconvulsive status epilepticus (NCSE) is scarce. One trial addressing management of refractory SE with deep general anesthesia was terminated early due to insufficient recruitment. Multicenter prospective registries, including the Sustained Effort Network for treatment of Status Epilepticus (SENSE), have shed some light on these questions, but many answers are still lacking, such as the influence exerted by distinct EEG patterns in NCSE on the outcome. We therefore initiated a new prospective multicenter observational registry to collect clinical and EEG data that combined may further help in clinical decision-making and defining SE.

Methods

Sustained effort network for treatment of status epilepticus/European Academy of Neurology Registry on refractory Status Epilepticus (SENSE-II/AROUSE) is a prospective, multicenter registry for patients treated for SE. The primary objectives are to document patient and SE characteristics, treatment modalities, EEG, neuroimaging data, and outcome of consecutive adults admitted for SE treatment in each of the participating centers and to identify factors associated with outcome and refractoriness. To reach sufficient statistical power for multivariate analysis, a cohort size of 3000 patients is targeted.

Discussion

The data collected for the registry will provide both valuable EEG data and information about specific treatment steps in different patient groups with SE. Eventually, the data will support clinical decision-making and may further guide the planning of clinical trials. Finally, it could help to redefine NCSE and its management.

Trial registration

NCT number: NCT05839418.
Appendix
Available only for authorised users
Literature
1.
2.
Hirsch LJ, Fong MW, Leitinger M, LaRoche SM, Beniczky S, Abend NS, et al. American Clinical Neurophysiology Society’s standardized critical care EEG terminology: 2021 version. J Clin Neurophysiol. 2021;38:1–29.PubMedPubMedCentralCrossRef
3.
Damien C, Cissé FA, Depondt C, Rikir E, Legros B, Gaspard N. Duration of nonconvulsive seizures in critically ill patients. Epilepsy Behav. 2021;124:108312.PubMedCrossRef
4.
Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based Guideline: treatment of Convulsive Status Epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16:48.PubMedPubMedCentralCrossRef
5.
Shorvon S, Baulac M, Cross H, Trinka E, Walker M. The drug treatment of status epilepticus in Europe: Consensus document from a workshop at the first London colloquium on Status Epilepticus. Epilepsia. 2008;49:1277–85.PubMedCrossRef
6.
Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011.
7.
Hirsch LJ, Gaspard N, van Baalen A, Nabbout R, Demeret S, Loddenkemper T, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related Epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018;59:739–44.PubMedCrossRef
8.
Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive Status Epilepticus. N Engl J Med. 1998;339:792–8.PubMedCrossRef
9.
Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, et al. A comparison of Lorazepam, diazepam, and Placebo for the treatment of out-of-hospital Status Epilepticus. N Engl J Med. 2001;345:631–7.PubMedCrossRef
10.
Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, et al. Intramuscular versus intravenous therapy for Prehospital Status Epilepticus. N Engl J Med. 2012;366:591–600.PubMedPubMedCentralCrossRef
11.
Guterman EL, Sanford JK, Betjemann JP, Zhang L, Burke JF, Lowenstein DH, et al. Prehospital midazolam use and outcomes among patients with out-of-hospital status epilepticus. Neurology. 2020;95:e3203–12.PubMedPubMedCentralCrossRef
12.
Gaínza-Lein M, Fernández IS, Ulate-Campos A, Loddenkemper T, Ostendorf AP. Timing in the treatment of status epilepticus: from basics to the clinic. Seizure. 2019;68:22–30.PubMedCrossRef
13.
Sathe AG, Underwood E, Coles LD, Elm JJ, Silbergleit R, Chamberlain JM, et al. Patterns of benzodiazepine underdosing in the established Status Epilepticus Treatment Trial. Epilepsia. 2021;62:795–806.PubMedPubMedCentralCrossRef
14.
Sairanen JJ, Kantanen AM, Hyppölä HT, Kälviäinen RK. Status epilepticus: practice variation and adherence to treatment guideline in a large community hospital. J Neurol Sci. 2021;427.
15.
Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, et al. Randomized Trial of three anticonvulsant medications for Status Epilepticus. N Engl J Med. 2019;381:E211–6.CrossRef
16.
Strzelczyk A, Zöllner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, et al. Lacosamide in status epilepticus: systematic review of current evidence. Epilepsia. 2017;58:933–50.PubMedCrossRef
17.
Husain AM. Treatment of recurrent Electrographic Nonconvulsive seizures (TRENdS) study. Epilepsia. 2013;54:84–8.PubMedCrossRef
18.
Husain AM, Lee JW, Kolls BJ, Hirsch LJ, Halford JJ, Gupta PK, et al. Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures. Ann Neurol. 2018;83:1174–85.PubMedPubMedCentralCrossRef
19.
Aicua-Rapun I, André P, Rossetti AO, Decosterd LA, Buclin T, Novy J. Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response. Epilepsy Res. 2019;149:88–91.PubMedCrossRef
20.
Strzelczyk A, Steinig I, Willems LM, Reif PS, Senft C, Voss M, et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav. 2017;70:177–81. Pt A.PubMedCrossRef
21.
Kalss G, Rohracher A, Leitinger M, Pilz G, Novak HF, Neuray C, et al. Intravenous brivaracetam in status epilepticus: a retrospective single-center study. Epilepsia. 2018;59(Suppl 2):228–33.PubMedCrossRef
22.
Santamarina E, Parejo Carbonell B, Sala J, Gutiérrez-Viedma Á, Miró J, Asensio M, et al. Use of intravenous brivaracetam in status epilepticus: a multicenter registry. Epilepsia. 2019;60:1593–601.PubMedCrossRef
23.
Orlandi N, Bartolini E, Audenino D, Moja MC, Urso L, D’Orsi G, et al. Intravenous brivaracetam in status epilepticus: a multicentric retrospective study in Italy. Seizure. 2021;86:70–6.PubMedCrossRef
24.
Orlandi N, Giovannini G, Rossi J, Cioclu MC, Meletti S. Clinical outcomes and treatments effectiveness in status epilepticus resolved by antiepileptic Drugs: a five-year observational study. Epilepsia open. 2020;5:166–75.PubMedPubMedCentralCrossRef
25.
De Stefano P, Baumann SM, Grzonka P, Sarbu OE, De Marchis GM, Hunziker S, et al. Early timing of anesthesia in status epilepticus is associated with complete recovery: a 7-year retrospective two-center study. Epilepsia. 2023;64:1493–506.PubMedCrossRef
26.
Rossetti AO, Milligan TA, Vulliémoz S, Michaelides C, Bertschi M, Lee JW. A Randomized Trial for the treatment of Refractory Status Epilepticus. Neurocrit Care. 2011;14:4–10.PubMedCrossRef
27.
28.
Bellante F, Legros B, Depondt C, Créteur J, Taccone FS, Gaspard N. Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety. J Neurol. 2016;263:799–806.PubMedCrossRef
29.
Fernandez A, Lantigua H, Lesch C, Shao B, Foreman B, Schmidt JM, et al. High-dose midazolam infusion for refractory status epilepticus. Neurology. 2014;82:359–65.PubMedPubMedCentralCrossRef
30.
Semmlack S, Tschudin-Sutter S, Widmer AF, Valença M, Rüegg S, Marsch S, et al. Independent impact of Infections on the course and outcome of status epilepticus: a 10-year cohort study. J Neurol. 2016;263:1303–13.PubMedCrossRef
31.
Sutter R, Marsch S, Fuhr P, Kaplan PW, Rüegg S. Anesthetic drugs in status epilepticus: Risk or rescue? 2014.
32.
Marchi NA, Novy J, Faouzi M, Stähli C, Burnand B, Rossetti AO. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med. 2015;43:1003–9.PubMedCrossRef
33.
Brigo F, Lattanzi S, Rohracher A, Russo E, Meletti S, Grillo E, et al. Perampanel in the treatment of status epilepticus: a systematic review of the literature. Epilepsy Behav. 2018;86:179–86.PubMedCrossRef
34.
Strzelczyk A, Knake S, Kälviäinen R, Santamarina E, Toledo M, Willig S, et al. Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain. Acta Neurol Scand. 2019;139:369–76.PubMedPubMedCentralCrossRef
35.
Fechner A, Hubert K, Jahnke K, Knake S, Konczalla J, Menzler K, et al. Treatment of refractory and superrefractory status epilepticus with topiramate: a cohort study of 106 patients and a review of the literature. Epilepsia. 2019;60:2448–58.PubMedCrossRef
36.
Apostolakopoulou L, Bosque Varela P, Rossini F, O’Sullivan C, Löscher W, Kuchukhidze G et al. Intravenous topiramate for seizure emergencies - first in human case report. Epilepsy Behav. 2023;142.
37.
Nelson SE, Varelas PN. Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus. 2018.
38.
Stetefeld HR, Schaal A, Scheibe F, Nichtweiß J, Lehmann F, Müller M, et al. Isoflurane in (Super-) refractory status Epilepticus: a multicenter evaluation. Neurocrit Care. 2021;35:631–9.PubMedPubMedCentralCrossRef
39.
Trinka E, Brigo F. Neurostimulation in the treatment of refractory and super-refractory status epilepticus. Epilepsy and Behavior. 2019;101.
40.
Trinka E, Brigo F. Neurostimulation in the treatment of refractory and super-refractory status epilepticus. Epilepsy Behav. 2019;101 Pt B.
41.
42.
Wickström R, Taraschenko O, Dilena RP ET, Specchio N, Nabbout R et al. International consensus recommendations for management of new onset refractory status epilepticus (NORSE) including febrile infection-related epilepsy syndrome (FIRES): Summary and clinical tools. Epilepsia. 2022;00:1–13.
43.
Holtkamp M, Masuhr F, Harms L, Einhäupl KM, Meierkord H, Buchheim K. The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neurologists. J Neurol Neurosurg Psychiatry. 2003;74:1095–9.PubMedPubMedCentralCrossRef
44.
45.
An J, Jonnalagadda D, Moura V, Purdon PL, Brown EN, Westover MB. Variability in pharmacologically-induced coma for treatment of refractory status epilepticus. PLoS ONE. 2018;13.
46.
47.
Shorvon S, Trinka E. Regulatory aspects of status epilepticus. Epilepsia. 2018;59(Suppl 2):128–34.PubMedCrossRef
48.
Dham BS, Hunter K, Rincon F. The epidemiology of status epilepticus in the United States. Neurocrit Care. 2014;20:476–83.PubMedCrossRef
49.
Kantanen AM, Sairanen J, Kälviäinen R. Incidence of the different stages of status epilepticus in Eastern Finland: a population-based study. Epilepsy Behav. 2019;101 Pt B.
50.
Leitinger M, Höller Y, Kalss G, Rohracher A, Novak HF, Höfler J, et al. Epidemiology-based mortality score in Status Epilepticus (EMSE). Neurocrit Care. 2015;22:273–82.PubMedCrossRef
51.
Kellinghaus C, Lang N, Rossetti AO, Rüegg S, Tilz C, Trinka E, et al. Making SENSE - sustained Effort Network for treatment of Status Epilepticus as a multicenter prospective registry. BMC Neurol. 2015;15:230.PubMedPubMedCentralCrossRef
52.
Kellinghaus C, Rossetti AO, Trinka E, Lang N, Unterberger I, Rüegg S, et al. SENSE registry for status epilepticus. Epilepsia. 2018;59:150–4.PubMedCrossRef
53.
Kellinghaus C, Rossetti AO, Trinka E, Lang N, May TW, Unterberger I et al. Sustained Effort Network for treatment of Status Epilepticus (SENSE) – a multicenter prospective observational registry. Epilepsy Behav. 2019;101.
54.
Kellinghaus C, Rossetti AO, Trinka E, Lang N, May TW, Unterberger I, et al. Factors predicting cessation of status epilepticus in clinical practice: data from a prospective observational registry (SENSE). Ann Neurol. 2019;85:421–32.PubMedCrossRef
55.
56.
Trinka E, Leitinger M. Management of Status Epilepticus, Refractory Status Epilepticus, and super-refractory Status Epilepticus. Continuum (Minneap Minn). 2022;28:559–602.PubMed
57.
Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40:120–2.PubMedCrossRef
58.
59.
Leitinger M, Trinka E, Gardella E, Rohracher A, Kalss G, Qerama E, et al. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. Lancet Neurol. 2016;15:1054–62.PubMedCrossRef
60.
Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95.PubMedPubMedCentralCrossRef
61.
Van Swieten JC, Koudstaal PJ, Visser MC, Schouten H, Van Gijn J. Interobserver agreement for the assessment of handicap in Stroke patients. Stroke. 1988;19:604–7.PubMedCrossRef
62.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef
63.
Rossetti AO, Logroscino G, Bromfield EB. A clinical score for prognosis of status epilepticus in adults. 2006.
64.
Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based Guideline: treatment of Convulsive Status Epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16:48–61.PubMedPubMedCentralCrossRef
65.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.PubMedCrossRef
66.
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95.
67.
Leitinger M, Trinka E, Giovannini G, Zimmermann G, Florea C, Rohracher A, et al. Epidemiology of status epilepticus in adults: a population-based study on incidence, causes, and outcomes. Epilepsia. 2019;60:53–62.PubMedCrossRef
68.
Claassen J, Taccone FS, Horn P, Holtkamp M, Stocchetti N, Oddo M. Recommendations on the use of EEG monitoring in critically ill patients: consensus statement from the neurointensive care section of the ESICM. Intensive Care Med. 2013;39:1337–51.PubMedCrossRef
Metadata
Title
Sustained effort network for treatment of status epilepticus/European academy of neurology registry on adult refractory status epilepticus (SENSE-II/AROUSE)
Authors
Charlotte Damien
Markus Leitinger
Christoph Kellinghaus
Adam Strzelczyk
Pia De Stefano
Christoph P. Beier
Raoul Sutter
Leena Kämppi
Daniel Strbian
Erik Taubøll
Felix Rosenow
Raimund Helbok
Stephan Rüegg
Maxwell Damian
Eugen Trinka
Nicolas Gaspard
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2024
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03505-y

Other articles of this Issue 1/2024

BMC Neurology 1/2024 Go to the issue

Study Protocol

Evaluating the effect of rapamycin treatment in Alzheimer’s disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol

Research

Spinal cord stimulation for postural abnormalities in Parkinson’s disease: 1-year prospective pilot study

Research

Intrathecal baclofen efficacy for managing motor function and spasticity severity in patients with cerebral palsy: a systematic review and meta-analysis

Research

Monocyte to high-density lipoprotein cholesterol ratio is associated with cerebral small vessel diseases

Research

Exploring the role of mitochondrial-associated and peripheral neuropathy genes in the pathogenesis of diabetic peripheral neuropathy

Study Protocol

Delays in Multiple Sclerosis diagnosis (DIMES): protocol for a multicentre, observational study of multiple sclerosis diagnostic pathways in the United Kingdom and Republic of Ireland